生物技术公司再鼎医药(09688)周四盘中大涨7.35%,引发市场关注。
引发上涨的主因是,高盛近期发布报告看好中国生物医疗科技行业,重点推荐再鼎医药等5家公司。报告预测,再鼎医药一款重点候选药物ZL-1310在2035年的全球风险调整后销售额将达3.44亿美元,反映市场对该公司长期增长前景的看好。
数据显示,当日早盘再鼎医药股价最高上涨5.21%,报22.2港元;全天成交量34.32万股,换手率0.03%。机构方面,11家给予评级的机构中有10家看好给予买入评级。投资者对再鼎医药的发展前景持续看好,推动当日股价走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.